Completado

Cytokine Expression in Allergic Asthma

0 criterios cumplidosConsulta de un vistazo cómo tu perfil cumple con cada criterio de elegibilidad.
Qué se está recopilando

Colección de datos

Quiénes están siendo reclutados

Enfermedades bronquiales+6

+ Hipersensibilidad

+ Hipersensibilidad inmediata

De 18 a 65 años
Ver todos los criterios de elegibilidad
Cómo está diseñado el estudio

Observacional
Inicio del estudio: septiembre de 1994
Ver detalles del protocolo

Resumen

Patrocinador PrincipalNational Institute of Allergy and Infectious Diseases (NIAID)
Última actualización: 2 de julio de 2017
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Fecha de inicio: 14 de septiembre de 1994

Fecha en la que se inscribió al primer participante.

In the last 10 years it has become generally accepted that asthma is an inflammatory disease of the airways. T lymphocytes play a key role in regulating this inflammatory response, through the elaboration of cytokines such as IL-4, IL-5, and IFN-gamma. IL-5 is of particular interest because it is the major eosinophil survival factor in vivo. Eosinophils are felt to be the major effector cells in asthma, causing damage to various airway structures. The pulmonary late phase response, a worsening of airflow seen 4-8 hours after allergen inhalation, is associated with many of the inflammatory changes seen in chronic asthma. Current studies suggest that during the late phase response peripheral blood T cells traffic to the lungs and express cytokines, specifically IL-4 and IL-5. We propose to investigate this trafficking by determining the frequencies and phenotype of cells capable of producing the above cytokines in the peripheral blood in subjects with mild allergic asthma. These studies should lead to a clearer understanding of the cells and processes that lead to T cell trafficking to the lung and may yield a tool to evaluate the proposed anti-inflammatory therapies for asthma.

NCT00001408
Patrocinador PrincipalNational Institute of Allergy and Infectious Diseases (NIAID)
Última actualización: 2 de julio de 2017
Extraido de una base de datos validada por el gobierno.Reclamar como socio

Protocolo

Esta sección proporciona detalles del plan del estudio, incluyendo cómo está diseñado y qué se está evaluando.
Detalles del Diseño

Se reclutarán 250 pacientes

Número total de participantes que el ensayo clínico espera reclutar.

Elegibilidad

Los investigadores buscan pacientes que cumplan ciertos criterios, conocidos como criterios de elegibilidad: estado general de salud o tratamientos previos.
Condiciones
Criterios

Cualquier sexo

Sexo biológico de los participantes elegibles para inscribirse.

De 18 a 65 años

Rango de edades de los participantes que pueden unirse al estudio.

Voluntarios sanos no permitidos

Indica si personas sanas, sin la condición que se estudia, pueden participar.

Condiciones

Patología

Enfermedades bronquialesHipersensibilidadHipersensibilidad inmediataEnfermedades del sistema inmunitarioEnfermedades del pulmónEnfermedades Pulmonares ObstructivasHipersensibilidad RespiratoriaEnfermedades del Tracto RespiratorioAsma

Criterios

INCLUSION CRITERIA - BLOOD DRAW/ASTHMA: Age 18-65. Asthma of greater than one year duration. Willingness to adhere to effective contraception in women of child bearing age. Negative HIV test. EXCLUSION CRITERIA - BLOOD DRAW/ASTHMA: For blood draws of greater than 100 ml, a hemoglobin of less than 12.5 g/dl. For blood draws of 100 ml or less, performed less frequently than every 56 days, a hemoglobin of less than 10.0 g/dl. Current pregnancy. Medical history suggesting lung diseases other than asthma. History of immunodeficiency or HIV infection. INCLUSION CRITERIA - BLOOD DRAW/NORMAL CONTROL: Age 18-65. Willingness to adhere to effective contraception in women of child bearing age. Negative HIV test. EXCLUSION CRITERIA - BLOOD DRAW/NORMAL CONTROL: For blood draws of greater than 100 ml, a hemoglobin of less than 12.5 g/dl. For blood draws of 100 ml or less, performed less frequently than every 56 days, a hemoglobin of less than 10.0 g/dl. Current pregnancy. Positive skin test to one or more allergens in the battery tested. History of asthma or other allergic diseases, such as hay fever. Medical history suggesting lung diseases other than asthma. History of immunodeficiency or HIV infection. INCLUSION CRITERIA - EXHALED BREATH CONDENSATE/ASTHMA: Age 18-65. Asthma as diagnosed by a physician or use of medications consistent with the treatment of asthma. Subjects must have a doctor outside NIH and they will provide routine and emergency care. EXCLUSION CRITERIA - EXHALED BREATH CONDENSATE/ASTHMA: History of immunodeficiency or HIV infection. History of allergy to latex. INCLUSION CRITERIA - EXHALED BREATH CONDENSATE/HEALTHY CONTROL: Age 18 - 65. EXCLUSION CRITERIA - EXHALED BREATH CONDENSATE/HEALTHY CONTROL: History of asthma or other allergic diseases, such as allergic rhinitis. Medical history suggesting lung diseases other than asthma. History of allergy to latex. History of immunodeficiency or HIV infection.

Centros del Estudio

Estos son los hospitales, clínicas o centros de investigación donde se lleva a cabo el estudio. Puedes encontrar la ubicación más cercana a ti y su estado de reclutamiento.

Este estudio tiene una ubicación

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, United StatesAbrir National Institutes of Health Clinical Center, 9000 Rockville Pike en Google Maps
Completado1 Centros de Estudio